Please login to the form below

Not currently logged in
Email:
Password:

anaesthetics

This page shows the latest anaesthetics news and features for those working in and with pharma, biotech and healthcare.

Acacia finally gets FDA okay for first product Barhemsys

Acacia finally gets FDA okay for first product Barhemsys

Meanwhile, the UK company is also preparing for a possible approval by 5 April of ByFavo (remimazolam), an ultra-short-acting and reversible intravenous benzodiazepine sedative/anaesthetic for use during procedural

Latest news

More from news
Approximately 1 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    200+. Janssen / J&J (US). Piramal (IN). Asset acquisition. 5 injectable pain / anaesthetic products.

  • Deal Watch September 2016 Deal Watch September 2016

    500. GSK / Aspen. Asset acquisition. Sale of anaesthetic drugs [Ultiva, Nimbex, Tracrium, Mivacron and Anectinein – excludes US/CA rights].

  • Deal Watch June 2016 Deal Watch June 2016

    Meanwhile AstraZeneca has out-licensed ex-US rights to a portfolio of seven anaesthetics to Aspen. ... Paying $520m upfront Aspen gains access to a series of local anaesthetics including Marcaine (bupivacaine) and Xylocaine (lidocaine/ lignocaine), and

  • Pharma deals in June 2015 Pharma deals in June 2015

    Neosaxitoxin, novel anaesthetic for local anaesthesia and post-op pain management. Collaboration, licence.

  • Pharma deals during March 2014 Pharma deals during March 2014

    Baxter's medical products business has annual sales of over $9bn and a portfolio of intravenous solutions and nutritional therapies, drug delivery systems, premixed and other injectable drugs, inhalation anaesthetics and

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics